Switching to hypomania and mania: Differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms

Current Psychiatry Reports

Volumn 12, Issue 6, 2010, Pages 512-521

  Chen, Jun ^a,b   Fang, Yiru ^b   Kemp, David E ^a   Calabrese, Joseph R ^a   Gao, Keming ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antidepressant; Bipolar disorder; Mechanism; Neurochemistry; Treatment emergent mania

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; AMINO ACID DERIVATIVE; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CORTICOSTEROID DERIVATIVE; DONEPEZIL; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; FLUOXETINE; HYDROCORTISONE; LITHIUM; LORAZEPAM; MELATONIN; MIFEPRISTONE; MONOAMINE DERIVATIVE; MOOD STABILIZER; PAROXETINE; PLACEBO; PROTIRELIN; QUETIAPINE; RILUZOLE; SEROTONIN 2C ANTAGONIST; SERTRALINE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; DEPRESSION; HUMAN; HYPOMANIA; MANIA; MONOTHERAPY; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NEUROPATHOLOGY; NEUROPSYCHOLOGY; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; HUMANS; NEUROTRANSMITTER AGENTS; TREATMENT OUTCOME;

EID: 78649914577     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0157-z     Document Type: Review

References (53)

1. •• Gao K, Kemp D, Calabrese J: Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy. Edited by Zarate CA Jr, Manji HK. Basel, Switzerland: Birkhauser Verlag AT; 2009:159-178. This book chapter summarizes the limitations of the current data in the maintenance treatment of BPD.
2. K Gao DE Kemp C Conroy, et al. 2010 Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients Int J Clin Pract 64 336 344 10.1111/j.1742-1241.2009.02284.x 20456174 1:CAS:528:DC%2BC3cXksVeqtb0%3D
3. RJ Baldessarini L Leahy S Arcona, et al. 2007 Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders Psychiatr Serv 58 85 91 10.1176/appi.ps.58.1.85 17215417
4. K Martinowich RJ Schloesser HK Manji 2009 Bipolar disorder: from genes to behavior pathways J Clin Invest 119 726 736 10.1172/JCI37703 19339764 1:CAS:528:DC%2BD1MXktlSnsbo%3D This is a good review of the neurobiology of BPD.
5. Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci 1995, 7:524-533; discussion 523-524.
6. PR Joyce DM Fergusson G Woollard, et al. 1995 Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder J Affect Disord 33 233 243 10.1016/0165-0327(94)00094-P 7790677 1:STN:280:DyaK2MzhtVKrtA%3D%3D
7. AF Arnsten 2007 Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness Cereb Cortex 17 Suppl 1 i6 i15 10.1093/cercor/bhm033 17434919
8. M Berk S Dodd M Kauer-Sant'anna, et al. 2007 Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder Acta Psychiatr Scand Suppl 434 41 49 10.1111/j.1600-0447.2007.01058.x 17688462 (Pubitemid 47241063)
9. IS Shiah LN Yatham 2000 Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies Bipolar Disord 2 77 92 10.1034/j.1399-5618.2000.020201.x 11252655 1:STN:280:DC%2BD3M3gs1Gnuw%3D%3D
10. S Sobczak A Honig MA van Duinen, et al. 2002 Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies Bipolar Disord 4 347 356 10.1034/j.1399-5618.2002.01217.x 12519094 1:CAS:528:DC%2BD3sXns1Snurg%3D (Pubitemid 36041464)
11. J Applebaum Y Bersudsky E Klein 2007 Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study Bipolar Disord 9 884 887 10.1111/j.1399-5618.2007.00466.x 18076538 1:CAS:528: DC%2BD1cXhtlShsbs%3D (Pubitemid 350215114)
12. DS Janowsky MK el-Yousef JM Davis 1974 Acetylcholine and depression Psychosom Med 36 248 257 4829619 1:STN:280:DyaE2c7mslOrtA%3D%3D
13. Eden Evins A, Demopulos C, Nierenberg A, et al.: A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 2006, 8:75-80.
14. DB Leiva 1990 The neurochemistry of mania: a hypothesis of etiology and rationale for treatment Prog Neuropsychopharmacol Biol Psychiatry 14 423 429 10.1016/0278-5846(90)90030-K 2193316 1:STN:280:DyaK3c3psFKhsg%3D%3D (Pubitemid 20191906)
15. Brambilla P, Perez J, Barale F, et al.: GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:721-737, 715. (Pubitemid 36976430)
16. Z Bhagwagar M Wylezinska P Jezzard, et al. 2007 Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects Biol Psychiatry 61 806 812 10.1016/j.biopsych.2006.08.048 17210135 1:CAS:528:DC%2BD2sXisVWhtbk%3D (Pubitemid 46330250)
17. RE Kaufman MJ Ostacher EH Marks, et al. 2009 Brain GABA levels in patients with bipolar disorder Prog Neuropsychopharmacol Biol Psychiatry 33 427 434 10.1016/j.pnpbp.2008.12.025 19171176 1:CAS:528:DC%2BD1MXjslKks7s%3D
18. F Curtin P Schulz 2004 Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis J Affect Disord 78 201 208 10.1016/S0165-0327(02)00317-8 15013244 1:CAS:528:DC%2BD2cXpsV2jtQ%3D%3D (Pubitemid 38167738)
19. BP Brennan JI Hudson JE Jensen, et al. 2009 Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole Neuropsychopharmacology 35 834 846 10.1038/npp.2009.191 19956089 1:CAS:528:DC%2BC3cXhtlCrtbk%3D The data from this study showed that open-label treatment with riluzole increased glutamine/glutamate ratios and levels of N-acetylaspartate in the anterior cingulate cortex. The reduction of depressive symptoms was positively associated with increases in N-acetylaspartate in the anterior cingulate cortex
20. MJ Lan GA McLoughlin JL Griffin, et al. 2009 Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder Mol Psychiatry 14 269 279 10.1038/sj.mp.4002130 18256615 1:CAS:528:DC%2BD1MXit1OktLk%3D
21. S Watson P Gallagher JC Ritchie, et al. 2004 Hypothalamic-pituitary- adrenal axis function in patients with bipolar disorder Br J Psychiatry 184 496 502 10.1192/bjp.184.6.496 15172943 (Pubitemid 38725709)
22. M Maj MG Ariano F Arena, et al. 1984 Plasma cortisol, catecholamine and cyclic AMP levels, response to dexamethasone suppression test and platelet MAO activity in manic-depressive patients. A longitudinal study Neuropsychobiology 11 168 173 10.1159/000118071 6089030 1:CAS:528:DyaL2cXlvV2hs7k%3D
23. AC Swann PE Stokes R Casper, et al. 1992 Hypothalamic-pituitary- adrenocortical function in mixed and pure mania Acta Psychiatr Scand 85 270 274 10.1111/j.1600-0447.1992.tb01468.x 1595360 1:CAS:528:DyaK38Xlt12hsrs%3D
24. AH Young P Gallagher S Watson, et al. 2004 Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder Neuropsychopharmacology 29 1538 1545 10.1038/sj.npp.1300471 15127079 1:CAS:528:DC%2BD2cXlvVSjtrs%3D (Pubitemid 38982247)
25. AT Spijker EF van Rossum E Hoencamp, et al. 2009 Functional polymorphism of the glucocorticoid receptor gene associates with mania and hypomania in bipolar disorder Bipolar Disord 11 95 101 10.1111/j.1399-5618.2008.00647.x 19133972 1:CAS:528:DC%2BD1MXivVGqs7o%3D Two variants of the glucocorticoid receptor gene were found to be associated with a protective effect on the manifestation of BPD, suggesting that a subgroup of patients may be vulnerable to manic/hypomanic switching.
26. I Extein AL Pottash MS Gold, et al. 1980 The thyroid-stimulating hormone response to thyrotropin-releasing hormone in mania and bipolar depression Psychiatry Res 2 199 204 10.1016/0165-1781(80)90077-3 6774358 1:CAS:528:DyaL3cXkt1equrw%3D (Pubitemid 10073893)
27. C Kirkegaard N Bjorum D Cohn, et al. 1978 Thyrotrophin-releasing hormone (TRH) stimulation test in manic-depressive illness Arch Gen Psychiatry 35 1017 1021 98129 1:STN:280:DyaE1c3jsVGgsg%3D%3D
28. R Bottlender D Rudolf A Strauss, et al. 2000 Are low basal serum levels of the thyroid stimulating hormone (b-TSH) a risk factor for switches into states of expansive syndromes (known in Germany as "maniform syndromes" in bipolar I depression)? Pharmacopsychiatry 33 75 77 10.1055/s-2000-7973 10761824 1:CAS:528:DC%2BD3cXjtVymsL0%3D (Pubitemid 30161110)
29. MP Szuba JD Amsterdam AT Fernando 3rd, et al. 2005 Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression J Clin Psychopharmacol 25 325 330 10.1097/01.jcp.0000169037.17884.79 16012274 1:CAS:528:DC%2BD2MXmtVaiu7s%3D (Pubitemid 41060251)
30. JR Calabrese JD Guelfi C Perdrizet-Chevallier 2007 Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data Bipolar Disord 9 628 635 10.1111/j.1399-5618.2007.00507.x 17845278 1:CAS:528:DC%2BD2sXht1aiu7nK (Pubitemid 47365631)
31. V Srinivasan SR Pandi-Perumal I Trakht, et al. 2009 Pathophysiology of depression: role of sleep and the melatonergic system Psychiatry Res 165 201 214 10.1016/j.psychres.2007.11.020 19181389 1:CAS:528:DC%2BD1MXhs1Chsr0%3D
32. D Sit KL Wisner BH Hanusa, et al. 2007 Light therapy for bipolar disorder: a case series in women Bipolar Disord 9 918 927 10.1111/j.1399-5618. 2007.00451.x 18076544 (Pubitemid 350215120)
33. RM Post GS Leverich 2006 The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention Dev Psychopathol 18 1181 1211 10.1017/S0954579406060573 17064434 1:STN:280:DC%2BD28njtVyqtg%3D%3D (Pubitemid 46394216)
34. N Horesh I Iancu 2010 A comparison of life events in patients with unipolar disorder or bipolar disorder and controls Compr Psychiatry 51 157 164 10.1016/j.comppsych.2009.05.005 20152296 The data from this study suggest that different psychological stressors may play a different role in the onset of a depressive episode and a manic/hypomanic episode.
35. K Gao D Muzina P Gajwani, et al. 2006 Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review J Clin Psychiatry 67 1327 1340 10.4088/JCP.v67n0902 17017818 1:CAS:528:DC%2BD28XhtFKqsL7P
36. J Mendlewicz 2009 Disruption of the circadian timing systems: molecular mechanisms in mood disorders CNS Drugs 23 Suppl 2 15 26 10.2165/11318630- 000000000-00000 19708722 1:CAS:528:DC%2BD1MXhtl2kurfI
37. SL McElroy RH Weisler W Chang, et al. 2010 A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry 71 163 174 10.4088/JCP.08m04942gre 20122366 1:CAS:528:DC%2BC3cXktVSgt7s%3D This is the largest randomized, double-blind, placebo-controlled study of antidepressant monotherapy in the acute treatment of bipolar depression. At a dose of paroxetine of 20 mg/d, the manic/hypomanic switching rate from paroxetine was low and similar to that of placebo.
38. V Agosti JW Stewart 2007 Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression Int Clin Psychopharmacol 22 309 311 10.1097/YIC.0b013e3280c28410 17690600 (Pubitemid 47237550)
39. JB Cohn G Collins E Ashbrook, et al. 1989 A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder Int Clin Psychopharmacol 4 313 322 10.1097/00004850-198910000-00006 2607128 1:STN:280:DyaK3c7htV2nug%3D%3D
40. JD Amsterdam J Shults 2010 Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study Am J Psychiatry 167 792 800 10.1176/appi.ajp.2009. 09020284 20360317 This is the largest study of antidepressant (fluoxetine) monotherapy in the acute and continuation treatment of bipolar II depression. At a dose of fluoxetine of 10 to 50 mg/d, the hypomanic switching rate was similar to that of placebo. Because the sample size was small, it is difficult to draw a firm conclusion.
41. CB Nemeroff DL Evans L Gyulai, et al. 2001 Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression Am J Psychiatry 158 906 912 11384898 1:STN:280: DC%2BD3MzhtFCnsg%3D%3D
42. P Keck Jr S Corya L Altshuler, et al. 2005 Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression J Clin Psychiatry 66 611 10.4088/JCP.v66n0511 15889948 1:CAS:528:DC%2BD2MXltlWgt7w%3D
43. GS Sachs AA Nierenberg JR Calabrese, et al. 2007 Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med 356 1711 1722 10.1056/NEJMoa064135 17392295 1:CAS:528:DC%2BD2sXkslCrtbY%3D (Pubitemid 46658703)
44. T Silverstone 2001 Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial Acta Psychiatr Scand 104 104 109 10.1034/j.1600-0447.2001.00240.x 11473503 1:CAS:528:DC%2BD3MXlvVKqsL8%3D (Pubitemid 32656085)
45. JD Amsterdam F Garcia-Espana J Fawcett, et al. 1998 Efficacy and safety of fluoxetine in treating bipolar II major depressive episode J Clin Psychopharmacol 18 435 440 10.1097/00004714-199812000-00003 9864074 1:CAS:528:DyaK1MXns1Km (Pubitemid 28555325)
46. JM Himmelhoch ME Thase AG Mallinger, et al. 1991 Tranylcypromine versus imipramine in anergic bipolar depression Am J Psychiatry 148 910 916 2053632 1:STN:280:DyaK3M3ntlWksw%3D%3D
47. RM Post LL Altshuler GS Leverich, et al. 2006 Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline Br J Psychiatry 189 124 131 10.1192/bjp.bp.105.013045 16880481 1:STN:280: DC%2BD28vls1ajtw%3D%3D (Pubitemid 44231270)
48. E Vieta A Martinez-Aran JM Goikolea, et al. 2002 A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers J Clin Psychiatry 63 508 512 12088162 1:CAS:528:DC%2BD38XlsFSrsrc%3D
49. GS Leverich LL Altshuler MA Frye, et al. 2006 Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers Am J Psychiatry 163 232 239 10.1176/appi.ajp.163.2.232 16449476 (Pubitemid 44480842)
50. E Brown DL Dunner SL McElroy, et al. 2009 Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression Int J Neuropsychopharmacol 12 773 782 10.1017/S1461145708009735 19079815 1:CAS:528:DC%2BD1MXntF2hsb8%3D
51. JR Calabrese RF Huffman RL White, et al. 2008 Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials Bipolar Disord 10 323 333 10.1111/j.1399-5618.2007.00500.x 18271912 1:CAS:528:DC%2BD1cXktVKnu70%3D (Pubitemid 351637697)
52. JF Goldberg CJ Truman 2003 Antidepressant-induced mania: an overview of current controversies Bipolar Disord 5 407 420 10.1046/j.1399-5618.2003.00067.x 14636364 1:CAS:528:DC%2BD2cXksVOiug%3D%3D (Pubitemid 38072243)
53. K Gao DE Kemp SJ Ganocy, et al. 2008 Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder Bipolar Disord 10 907 915 10.1111/j.1399-5618.2008.00637.x 19594506